Maze Therapeutics Prices $150M Public Offering to Fund R&D and Extend Cash Runway

summarizeSummary

Maze Therapeutics has finalized the pricing of a $150 million public offering of common stock and pre-funded warrants, securing capital to advance its clinical programs and extend its operational runway into 2029.

check_boxKey Events

• Finalizes $150 Million Public Offering

  Maze Therapeutics priced a public offering of 5,540,000 shares of common stock and pre-funded warrants to purchase 850,000 shares, raising approximately $144.7 million in net proceeds. This finalizes the terms of the offering initiated with the S-3ASR on February 4, 2026, and announced in an 8-K earlier today.

• Shares Priced at Discount

  The common stock and pre-funded warrants were offered at $23.50 per share and $23.499 per warrant, representing a discount to the last reported sale price of $25.69 on April 21, 2026.

• Extends Cash Runway into 2029

  Proceeds are primarily allocated to advance research and development for product candidates MZE829 and MZE782, and for general corporate purposes, extending the company's cash runway into 2029.

• Significant Share Dilution

  The offering introduces 6,390,000 new shares (including warrant exercisable shares), representing approximately 12.95% dilution based on 49,335,551 shares outstanding as of December 31, 2025.

auto_awesomeAnalysis

This 424B5 filing finalizes the terms and pricing of a significant public offering, following the initial S-3ASR registration on February 4, 2026, and the 8-K announcement earlier today. The company is raising approximately $144.7 million in net proceeds by selling 5,540,000 shares of common stock and pre-funded warrants to purchase an additional 850,000 shares, priced at $23.50 per share and $23.499 per warrant. This offering represents a substantial capital infusion, providing critical funding for the advancement of its MZE829 and MZE782 clinical programs and extending its cash runway into 2029. While the offering is dilutive to existing shareholders, the capital raise is essential for a clinical-stage biopharmaceutical company with a previously projected cash runway of only one year, as noted in its last 10-K. The pricing at a discount to the prior day's closing price reflects the necessity of the capital raise.